Trends in antifungal susceptibility among Candida sp. urinary isolates from 1994 and 1998

Journal of Clinical Microbiology

Volumn 38, Issue 2, 2000, Pages 870-871

  Baran Jr , Joseph ^a   Klauber, Enid ^a   Barczak, Jeffrey ^a   Riederer, Kathleen ^a   Khatib, Riad ^a  

^a ST JOHN HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; UK 049858; UNCLASSIFIED DRUG; VORICONAZOLE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA TROPICALIS; FUNGUS IDENTIFICATION; HUMAN; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; URINARY TRACT;

CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA TROPICALIS; FUNGI;

EID: 0033952848     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/jcm.38.2.870-871.2000     Document Type: Article

References (11)

1. Ayeni, O., K. M. Riederer, F. M. Wilson, and R. Khatib, 1999. Clinicians reactions to positive urine culture for Candida organisms. Mycoses 42:285-289.
2. Barry, A. L., and S. D. Brown. 1996. In vitro studies of two triazole antifungal agents (voriconazole [UK-109,496] and fluconazole) against Candida species. Antimicrob. Agents Chemother. 40:1948-1949.
3. Berrouane, V. F., L. A. Herwaldt, and M. A. Pfaller. 1999. Trends in antifungal use and epidemiology of nosocomial yeast infections in a university hospital. J. Clin. Microhiol. 37:531-537.
4. Fan-Harvard, P., D. Capano, S. M. Smith, et al. 1991. Development of resistance in Candida isolates from patients receiving prolonged antifungal therapy. Antimicrob. Agents Chemother. 35:2302-2305.
5. Franz, R., S. L. Kelly, D. C. Lamb, D. E. Kelly, M. Ruhnke, and J. Morschhauser. 1998. Multiple molecular mechanisms contribute to a stepwise development of fluconazole resistance in clinical Candida albicans strains. Antimicrob. Agents Chemother. 42:3065-3072.
6. Ghannoum, M. A., J. H. Rex, and J. N. Galgiani. 1996. Susceptibility testing of fungi: current status of correlation of in vitro data with clinical outcome. J. Clin. Microbiol. 34:489-495.
7. Johnson, E. M., and D. W. Warnock. 1995. Azole drug resistance in yeasts. J. Antimicrob. Chemother. 36:751-755.
8. National Committee for Clinical Laboratory Standards. 1997. Reference method for broth dilution antifungal susceptibility testing of yeast. Approved standard M27-A. National Committee for Clinical Laboratory Standards, Villanova, Pa.
9. Pfaller, M. A., J. H. Rex, and M. G. Rinaldi. 1997. Antifungal susceptibility testing: technical advances and potential clinical applications. Clin. Infect. Dis. 24:776-784.
10. Pfaller, M. A., R. N. Jones, G. V. Doern, H. S. Sader, R. J. Hollis, and S. A. Messer for the Sentry Participant Group. 1998. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and antifungal susceptibilities of isolates collected in 1997 in the United States, Canada, and South America for the SENTRY Program. J. Clin. Microbiol. 36:1886-1889.
11. Witthuhn, F., D. Toubas, I. Beguinot, D. Aubert, C. Rouger, G. Remy, and J. M. Pinon. 1999. Evaluation of the Fungitest kit by using strains from human immunodeficiency virus-infected patients: study of azole drug susceptibility. J. Clin. Microbiol. 37:865-866.